http://purl.org/np/RAMN55yX7v_kIyC5bC1-vOm8BlSlME6YpMbaGxs5rzh3A#Head http://purl.org/np/RAMN55yX7v_kIyC5bC1-vOm8BlSlME6YpMbaGxs5rzh3A http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAMN55yX7v_kIyC5bC1-vOm8BlSlME6YpMbaGxs5rzh3A#assertion http://purl.org/np/RAMN55yX7v_kIyC5bC1-vOm8BlSlME6YpMbaGxs5rzh3A http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAMN55yX7v_kIyC5bC1-vOm8BlSlME6YpMbaGxs5rzh3A#provenance http://purl.org/np/RAMN55yX7v_kIyC5bC1-vOm8BlSlME6YpMbaGxs5rzh3A http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAMN55yX7v_kIyC5bC1-vOm8BlSlME6YpMbaGxs5rzh3A#pubinfo http://purl.org/np/RAMN55yX7v_kIyC5bC1-vOm8BlSlME6YpMbaGxs5rzh3A http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAMN55yX7v_kIyC5bC1-vOm8BlSlME6YpMbaGxs5rzh3A#assertion http://purl.obolibrary.org/obo/DOID_1826 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAMN55yX7v_kIyC5bC1-vOm8BlSlME6YpMbaGxs5rzh3A#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_1826 http://purl.org/np/RAMN55yX7v_kIyC5bC1-vOm8BlSlME6YpMbaGxs5rzh3A#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAMN55yX7v_kIyC5bC1-vOm8BlSlME6YpMbaGxs5rzh3A#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB00555 http://purl.org/np/RAMN55yX7v_kIyC5bC1-vOm8BlSlME6YpMbaGxs5rzh3A#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAMN55yX7v_kIyC5bC1-vOm8BlSlME6YpMbaGxs5rzh3A#association http://www.w3.org/2000/01/rdf-schema#label lamotrigine tablets is an antiepileptic drug aed indicated for epilepsy adjunctive therapy in patients 2 years of age 1 1 partial seizures primary generalized tonic clonic seizures generalized seizures of lennox gastaut syndrome conversion to monotherapy in patients with partial seizures who are receiving treatment with carbamazepine phenobarbital phenytoin primidone or valproate as the single aed epilepsy monotherapy in patients 16 years of age 1 1 maintenance treatment of bipolar i disorder to delay the time to occurrence of mood episodes in patients treated for acute mood episodes with standard therapy bipolar disorder in patients 18 years of age 1 2 adjunctive therapy lamotrigine tablets are indicated as adjunctive therapy for the following seizure types in patients 2 years of age partial seizures primary generalized tonic clonic seizures generalized seizures of lennox gastaut syndrome monotherapy lamotrigine tablets are indicated for conversion to monotherapy in adults 16 years of age with partial seizures who are receiving treatment with carbamazepine phenytoin phenobarbital primidone or valproate as the single antiepileptic drug aed safety and effectiveness of lamotrigine tablets have not been established 1 as initial monotherapy 2 for conversion to monotherapy from aeds other than carbamazepine phenytoin phenobarbital primidone or valproate or 3 for simultaneous conversion to monotherapy from 2 or more concomitant aeds lamotrigine tablets are indicated for the maintenance treatment of bipolar i disorder to delay the time to occurrence of mood episodes depression mania hypomania mixed episodes in adults 18 years of age treated for acute mood episodes with standard therapy the effectiveness of lamotrigine tablets in the acute treatment of mood episodes has not been established the effectiveness of lamotrigine tablets as maintenance treatment was established in 2 placebo controlled trials in patients with bipolar i disorder as defined by dsm iv the physician who elects to prescribe lamotrigine tablets for periods extending beyond 16 weeks should periodically re evaluate the long term usefulness of the drug for the individual patient see clinical studies 14 2 http://purl.org/np/RAMN55yX7v_kIyC5bC1-vOm8BlSlME6YpMbaGxs5rzh3A#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RAMN55yX7v_kIyC5bC1-vOm8BlSlME6YpMbaGxs5rzh3A#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAMN55yX7v_kIyC5bC1-vOm8BlSlME6YpMbaGxs5rzh3A#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB00555 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAMN55yX7v_kIyC5bC1-vOm8BlSlME6YpMbaGxs5rzh3A#provenance http://purl.org/np/RAMN55yX7v_kIyC5bC1-vOm8BlSlME6YpMbaGxs5rzh3A#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAMN55yX7v_kIyC5bC1-vOm8BlSlME6YpMbaGxs5rzh3A#pubinfo http://purl.org/np/RAMN55yX7v_kIyC5bC1-vOm8BlSlME6YpMbaGxs5rzh3A#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAMN55yX7v_kIyC5bC1-vOm8BlSlME6YpMbaGxs5rzh3A#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RAMN55yX7v_kIyC5bC1-vOm8BlSlME6YpMbaGxs5rzh3A#sig http://purl.org/nanopub/x/hasSignature hyR0u8KVudKTUeU0cU2TlTq5bTaRsnrw+wvhGGdxrr1Mkf3JS5V46fWjfkjdcaz4h8zgA4pFOMRq3RF32XsyjJzt4QAEqQ7LD3Qe54HDpwc7H2XB7X1G+dVYezPTEWiy4JphIVHvWHRamaGpISZCVNc5tOiYs+WCYznKMZaEc3Q= http://purl.org/np/RAMN55yX7v_kIyC5bC1-vOm8BlSlME6YpMbaGxs5rzh3A#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAMN55yX7v_kIyC5bC1-vOm8BlSlME6YpMbaGxs5rzh3A http://purl.org/np/RAMN55yX7v_kIyC5bC1-vOm8BlSlME6YpMbaGxs5rzh3A http://purl.org/dc/terms/created 2021-06-12T16:14:27.284+02:00 http://purl.org/np/RAMN55yX7v_kIyC5bC1-vOm8BlSlME6YpMbaGxs5rzh3A http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAMN55yX7v_kIyC5bC1-vOm8BlSlME6YpMbaGxs5rzh3A https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAMN55yX7v_kIyC5bC1-vOm8BlSlME6YpMbaGxs5rzh3A https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAMN55yX7v_kIyC5bC1-vOm8BlSlME6YpMbaGxs5rzh3A https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs